Αρχειοθήκη ιστολογίου

Αναζήτηση αυτού του ιστολογίου

Πέμπτη 7 Απριλίου 2016

Hybrid MR/PET Imaging in Neurology: Present Applications and Prospects for the Future



from #Medicine via ola Kala on Inoreader http://ift.tt/1ShXMUe
via IFTTT

Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis

Background: Radiolabelled prostate specific membrane antigen (PSMA) ligands represent a true theranostics concept for diagnosis and therapy of relapsed and metastatic prostate cancer patients. The aim of this study was to evaluate response and tolerability of a single dose of 177Lutetium-PSMA-617 (Lu-PSMA) in a large cohort of patients with metastatic castration resistant prostate cancer (mCRPC). Methods: The data of 82 consecutive patients (median age: 73 years, range: 43-87) with metastatic castration resistant prostate cancer who received a single dose of Lu-PSMA (mean: 5.9±0.5 GBq) were retrospectively analyzed. Data was collected at baseline and 8 weeks after therapy. 68Ga-PSMA-11 PET/CT was performed in all patients to verify sufficient PSMA expression. Bone, lymph node, liver and lung metastases were present in 99%, 65%, 17% and 11% of the patients, respectively. Tolerability and response were evaluated using hematologic parameters, renal scintigraphy, clinical data and prostate specific antigen (PSA) value at baseline and 8 weeks after therapy application. Results: A total of six patients died and two patients dropped out not willing to continue therapy and follow-up. Complete dataset of 74 patients were available for analysis. 47 (64%) of the patients showed a PSA-Decline, of these 23 (31%) had a PSA decline > 50%, 35 (47%) had a stable disease with a PSA decline from <50% to an increase <25% and 17 (23%) showed a progressive disease with a PSA increase >25%. There were no significant changes indicative of toxicity in hemoglobin, white blood cells, creatinine and tubular extraction rates. There was a significant but mild decrease of platelets with a median value still within the normal range. Conclusion: This retrospective multicenter analysis suggests that radioligand therapy with Lu-PSMA is safe, well tolerated and shows considerable response in PSA values. Therefore, it offers an additional therapeutic option for patients with mCRPC. This data may justify further prospective randomized studies to evaluate and prove the clinical benefit in survival and quality of life.



from #Medicine via ola Kala on Inoreader http://ift.tt/1MXDNOK
via IFTTT

The Thymidine Phosphorylase Imaging Agent 123I-IIMU Predicts the Efficacy of Capecitabine

Recently, companion diagnostics with nuclear medicine techniques are expected as more suitable means than biopsy for predicting treatment efficacy. The anti-cancer effect of capecitabine, an orally administered chemotherapeutic agent activated by thymidine phosphorylase (TP), positively correlates with tumor TP expression levels. This study aimed to assess whether TP imaging using a radiolabeled uracil derivative, [123I]5-iodo-6-[(2-iminoimidazolidinyl)methyl]uracil ([123I]IIMU), could predict the efficacy of capecitabine treatment. Methods: Sensitivity to doxifluridine, a metabolite of capecitabine and direct substrate for TP, was assessed by WST assays in vitro for three human colon cancer cell lines with different TP expression profiles. The intracellular uptake and retention of [123I]IIMU were evaluated. Mice inoculated with each cell line were treated with capecitabine for 2 weeks, and tumor growth was compared. In vivo distribution studies and single photon emission computed tomography/computed tomography imaging of [123I]IIMU were performed in inoculated mice. Results: In vitro experiments showed a positive correlation between TP expression levels and doxifluridine sensitivity. In vitro studies revealed that intracellular uptake and retention of [123I]IIMU were dependent on TP expression levels. In vivo experiments in inoculated mice showed that [123I]IIMU accumulation in tumor tissue was correlated with TP expression levels and susceptibility to capecitabine treatment. Moreover, single photon emission computed tomography/computed tomography imaging of [123I]IIMU in tumor-inoculated mice showed that [123I]IIMU reflects TP expression levels in tumor tissues. Conclusion: [123I]IIMU could be used as an in vivo companion diagnostic for predicting the efficacy of capecitabine treatment.



from #Medicine via ola Kala on Inoreader http://ift.tt/1ShXMDU
via IFTTT

Administered Activities for Pediatric Nuclear Medicine Procedures and the Impact of the 2010 North American Guidelines on General Hospitals in the United States

We sought to describe the practice of pediatric nuclear medicine at general hospitals in the US and to assess the impact of dose awareness campaigns like Image Gently. METHODS: A web-based survey was developed that requested information regarding hospital type, whether they practiced pediatric nuclear medicine, and their method for determining the administered activity for children. The survey invitation was emailed to a sample of general hospitals with more than 300 beds excluding dedicated pediatric, veterans, psychiatric and rehabilitation hospitals. Data were collected for 5 procedures performed in children: 99mTc MDP bone scans, 99mTc MAG3 renograms, 99mTc DMSA renal cortical scans, 99mTc based hepatobiliary scans, and 18F FDG PET scans. The sites reported dosage by weight (MBq/kg), minimum and maximum dosages and the activities that they would administer to 2 hypothetical patients: a 5 year old boy (20 kg, 110 cm tall) and a 10 year old girl (30 kg, 140 cm tall). RESULTS: The invitation was delivered to 196 sites with 121 (61.7%) responding. Eighty-two hospitals (67.8%) performed nuclear medicine in children. All sites scaled administered activity for children, mostly by body weight. Also, 82.4% of sites indicated they were familiar with Image Gently, 57.1% were familiar with the 2010 North American Guidelines for children, and 54.9% altered their protocols because of the Guidelines. The median value for parameters defined by the Guidelines was equal to the Guidelines recommended value for all sites. More than 50% of these sites were compliant with the Guidelines regarding both the acquisition parameters and the administered activities for the two hypothetical patients, particularly sites familiar with the Guidelines. However, there remained a wide variation in practice, sometimes more than a factor of 10, for sites not familiar with the Guidelines. CONCLUSION: Image Gently and the North American Guidelines have had a substantial impact on pediatric nuclear medicine practice in the US. However, a wide variation in practice still exists, particularly for sites not familiar with the Guidelines. Further promotion and dissemination of the Guidelines and best practice is still necessary.



from #Medicine via ola Kala on Inoreader http://ift.tt/1MXDNOF
via IFTTT

Anti-3-[18F] FACBC (Fluciclovine) PET-CT of Breast Cancer An Exploratory Study

The purpose of this study is to explore the uptake of the synthetic amino acid analog positron emission tomography (PET) radiotracer anti-3-[18F] FACBC (fluciclovine) in breast lesions with correlation to histologic and immunohistochemical characteristics. Methods: Twelve women with breast lesions underwent 45 minute dynamic PET-CT of the thorax after intravenous administration of 366.3 ±14.8 (337.44 - 394.05) MBq of fluciclovine. Uptake in the primary lesions at 4 representative time points (5, 17, 29, 41 min) after injection were correlated with histologic, imaging, and clinical findings. The significance of differences in maximum standard uptake value (SUVmax) and tumor to background ratios between malignant and benign tissue were calculated. Correlation of activity to histologic and immunohistochemical cancer subtypes were made including Ki-67 intensity and Nottingham Grade (NG). Results: There were 17 breast lesions (4 benign, 13 malignant) including 7/13 invasive ductal, 5/13 invasive lobular, and 1/13 metaplastic carcinomas. There was a significant difference in mean SUVmax ± standard deviation (SD) of malignant (6.15±3.2, 6.01±3.15, 5.68±2.82, and 5.59±2.95) vs benign (1.26±0.57, 1.21±0.53, 1.22±0.57 and 1.11±0.54) lesions at 5, 17, 29 and 41mins respectively (all p≤0.0001). Tumor to background (aorta, normal breast and marrow) ratios were also significantly higher in malignant compared to benign breast lesions (all P≤0.02). Highest fluciclovine activity seems to be present in triple negative and NG3 subtypes. Across time points, quantitative Ki-67 had weak positive correlation with SUVmax [R1=0.48(P = 0.03), R2=0.44(P = 0.03), R3= 0.46(P = 0.03), R4 =0.43(0.06)]. In 7 patients, fluciclovine PET visualized locoregional and distant spread including that of lobular cancer, though identification of hepatic metastases was limited by physiologic background activity. Conclusion: The uptake characteristics of fluciclovine are reflective of the histologic and immunohistochemical characteristics in suspect breast lesions with greater activity in malignant versus benign etiology. The data from this exploratory study may be useful to design future studies utilizing fluciclovine PET for breast tumor imaging as well as for detection of locoregional and distant spread



from #Medicine via ola Kala on Inoreader http://ift.tt/1ShXLzM
via IFTTT

Serial quantitative TSPO-targeted PET reveals peak microglial activation up to two weeks after an epileptogenic brain insult.

Experimental and clinical evidence suggests that neuroinflammation, triggered by epileptogenic insults, contributes to seizure development. We employed TSPO-targeted molecular imaging to obtain further insights into the role of microglial activation during epileptogenesis. Methods: As epileptogenic insult, a status epilepticus (SE) was induced in rats by lithium-pilocarpine. Rats were subjected to [11C]PK11195 PET scans before SE, immediately after SE, at 1, 2, 5, 7, 14, and 22 days, and 14-16 weeks post SE. For data evaluation, brain regions were outlined by co-registration with a standard rat brain atlas, and % injected dose/cc and binding potential (simplified reference tissue model with cerebellar gray matter as reference region) were calculated. For autoradiography and immunohistochemical evaluation, additional rats were decapitated without prior SE or 2, 5 or 14 days post SE. Results: Following SE, increases in [11C]PK11195 uptake and binding potential were evident in epileptogenesis-associated brain regions, such as hippocampus, thalamus or piriform cortex, but not in the cerebellum beginning at 2-5 days and persisting at least 3 weeks after SE. Maximal regional signal was observed at 1-2 weeks after SE. Autoradiography confirmed the spatiotemporal profile. Immunohistochemical evaluation revealed microglial and astroglial activation as well as neuronal cell loss in epileptogenesis-associated brain regions at all investigated time points. The time course of microglial activation was consistent with that demonstrated by tracer techniques. Principal Conclusion: TSPO-targeted PET is a reliable tool for identifying brain inflammation during epileptogenesis. Neuroinflammation mainly affects brain regions commonly associated with seizure generation and spread. Definition of the time profile of neuroinflammation may facilitate the development of inflammation-targeted, anti-epileptogenic therapy.



from #Medicine via ola Kala on Inoreader http://ift.tt/1MXDNOz
via IFTTT

Modulation of abnormal metabolic brain networks by experimental therapies in a nonhuman primate model of Parkinsons disease: an application to human retinal pigment epithelial (hRPE) cell implantation

Abnormal covariance pattern of regional metabolism associated with Parkinson's disease (PD) is modulated by dopaminergic pharmacotherapy. Using high resolution FDG PET and network analysis we previously derived and validated a parkinsonism-related metabolic pattern (PRP) in non-human primate models of PD. It is currently not known whether this network is modulated by experimental therapeutics. In this study we examined changes in network activity by striatal implantation of human levodopa-producing retinal pigment epithelial (hRPE) cells in parkinsonian macaques and evaluated its reproducibility in a small test-retest study. Methods: PET FDG scans were acquired in eight healthy macaques and eight macaques with MPTP-induced bilateral nigrostriatal dopaminergic lesions following unilateral putaminal implantation of hRPE cells or sham surgery. PRP activity was measured prospectively in all animals and in a subset of test-retest animals using a network quantification approach. Network activity and regional metabolic values were compared on a hemispheric basis between animal groups and treatment conditions. Results: All individual macaques had sustained clinical improvement after hRPE-implantation compared to the sham surgery. PRP activity was elevated in the untreated MPTP hemispheres relative to those of the normal controls (P < 0.00005) but was reduced (P < 0.05) in the hRPE-implanted hemispheres. The modulation observed in network activity was supported by concurrent local and remote changes in regional glucose metabolism. PRP activity remained unchanged in the untreated MPTP hemispheres versus the sham-operated hemispheres. PRP activity was also stable (P ≥ 0.29) and correlated (R2 ≥ 0.926; P < 0.00005) in the test-retest hemispheres. These findings were highly reproducible across several PRP topographies generated in multiple cohorts of parkinsonian and healthy macaques. Conclusion: We have demonstrated long-term therapeutic effects of hRPE cell implantation in non-human primate models of PD. The implantation of such levodopa-producing cells can concurrently decrease the elevated metabolic network activity in parkinsonian brains on an individual basis. These results parallel the analogous findings reported in patients with PD undergoing levodopa therapy and other symptomatic interventions. With further validation in large samples, FDG PET imaging with network analysis may provide a viable biomarker for assessing treatment response in animal models of PD following experimental therapies.



from #Medicine via ola Kala on Inoreader http://ift.tt/1ShXLzF
via IFTTT